Objectives Sequential combination of epidermal growth factor receptor (EGFR)-tyrosine
kinase inhibitors (TKIs) and chemotherapy has shown greater benefits than either treatment …

An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in
non-small cell lung cancer patients with tumors showing high EGFR gene copy number - PMC …

Purpose: Gefitinib plays an important role in non‐small‐cell lung cancer (NSCLC) treatment;
however, progression of the disease occurs in most patients even after an initial response …

Background Patients with epidermal growth factor receptor (EGFR) activation mutation-
positive non-small-cell lung cancer (NSCLC) respond well to EGFR tyrosine kinase …

Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …

9107 Background: Synergistic anti-tumor effect of double blocking EGFR and VEGF
pathways is proven by preclinical and clinical data. This study evaluated whether an …

Objectives Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are
particularly effective in non-small cell lung cancer (NSCLC) patients harboring active EGFR …

Backgrounds Efficacy of gefitinib therapy strongly depends on epidermal growth factor
receptor (EGFR)-mutation status in Asian patients with non-small cell lung cancer. Recently …

The study's goal is to evaluate the effectiveness of erlotinib in patients with EGFR mutant
metastatic non-small cell lung cancer (mNSCLC). The patient's medical data were analyzed …

Objectives Progression-free survival (PFS) and response rate to epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs) varies in patients with non-small-cell lung …